Treatment of Patients With Blepharitis and Facial Rosacea

This study is currently recruiting participants.

Verified by CollaGenex Pharmaceuticals, April 2008

First Received: November 16, 2007 Last Updated: April 16, 2008 History of Changes

Sponsored by:	CollaGenex Pharmaceuticals
Information provided by:	CollaGenex Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00560703

Purpose

To determine the safety and efficacy of sub-antimicrobial dose doxycycline in the treatment of patients who have both blepharitis and facial rosacea

Condition	Intervention	Phase
Blepharitis Meibomianitis Dry Eye	Drug: doxycycline Drug: placebo	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea

Resource links provided by NLM:

MedlinePlus related topics: Rosacea

Drug Information available for: Doxycycline Doxycycline hyclate Doxycycline calcium

Further study details as provided by CollaGenex Pharmaceuticals:

Primary Outcome Measures:

Change in Ocular Surface Disease Index Change in bulbar conjunctival hyperemia [ Time Frame: Baseline to end of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change in Schirmer tear test at each study visit Change in tear break-up time at each study visit Change in meibum character/fluidity at each study visit Change in meibomian gland inspissation at each study visit [ Time Frame: Baseline to end of study ] [ Designated as safety issue: No ]

Estimated Enrollment:	72
Study Start Date:	November 2007
Estimated Study Completion Date:	October 2008
Estimated Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Active Comparator doxycycline	Drug: doxycycline A. Oracea (doxycycline, USP) Capsules 40 mg, once per day for 84 days
P: Placebo Comparator Sugar capsule	Drug: placebo Once per day for 84 days

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00560703

Locations

United States, Arkansas
Pleasant Valley Ophthalmology	Recruiting
Little Rock, Arkansas, United States, 72212
Contact: Laurie Barber, M.D. 501-686-5150 lbarber66@yahoo.com
Principal Investigator: Laurie Barber, M.D.
United States, Florida
Warren Scherer, MD	Recruiting
Naples, Florida, United States, 34103
Contact: Warren Scherer, MD 239-261-8383
United States, Kentucky
Kentucky Lions Eye Center	Recruiting
Louisville, Kentucky, United States, 40202
Contact: Xiamo Wang 502-852-3826 gnawomaix@gmail.com
Principal Investigator: Gary Foulks, MD
United States, Missouri
Washington University School of Medicine	Recruiting
St. Louis, Missouri, United States, 63110
Contact: Adina O'Neal 314-747-8014 oneala@vision.wustl.edu
Principal Investigator: Andrew Huang, MD
United States, New York
Marguerite McDonald, MD	Recruiting
Lynbrook, New York, United States, 11563
Contact: Carla Del Castillo 516-593-4026
United States, Oklahoma
Dean McGee Eye Institute	Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Misty Youngblood 405-271-6307 misty-youngblood@dmei.org
Principal Investigator: James Chodosh, MD
United States, Pennsylvania
Anita Nevyas-Wallace, MD	Recruiting
Bala Cynwyd, Pennsylvania, United States, 19004
Contact: Anita Nevyas-Wallace, MD 610-668-2777
United States, Utah
Tanner Clinic	Recruiting
Layton, Utah, United States, 84041
Contact: Amanda Tinsley 801-773-4840 ext 3741 amandaetinsley@yahoo.com
Principal Investigator: Lance Nelson, MD

Sponsors and Collaborators

CollaGenex Pharmaceuticals

Investigators

Study Chair:

Angel Angelov, MD

CollaGenex Pharmaceuticals

More Information

No publications provided

Responsible Party:	CollaGenex Pharmaceuticals, Inc. ( Christopher Powala, Vice President, Drug Development and Regulatory Affairs )
Study ID Numbers:	COL-101-BLEPH-201
Study First Received:	November 16, 2007
Last Updated:	April 16, 2008
ClinicalTrials.gov Identifier:	NCT00560703 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Antimalarials
Anti-Bacterial Agents
Rosacea
Facies

Eye Diseases
Blepharitis
Doxycycline

Additional relevant MeSH terms:

Antimalarials
Anti-Infective Agents
Anti-Bacterial Agents
Antiparasitic Agents
Antiprotozoal Agents
Therapeutic Uses

Eye Diseases
Eyelid Diseases
Blepharitis
Pharmacologic Actions
Doxycycline

ClinicalTrials.gov processed this record on July 02, 2009